
|Articles|September 1, 2003
Test of Time Points to Durability of Efalizumab Efficacy and Safety
Chicago - The Biologics License Application for efalizumab (Raptiva) for the treatment of moderate-to-severe plaque psoriasis is set to undergo review by the FDA Dermatologic and Ophthalmic Drugs Advisory Committee this month.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
The “6-7” Advances for Dermatologists to Look Forward to in 2026
2
Exploring Type 2 Inflammation and Psoriasis Management at Horizons in Advanced Practice
3
Quoin Targets World’s First Approval for Netherton Syndrome Therapy in Saudi Arabia
4
Soquelitinib Phase 1 Data Show Sustained Clinical Improvement With Extended Treatment in AD
5



















